Correction: Comparative efficacy and safety of seven Chinese patent medicines combined with SSRIs for depressive disorder: a systematic review and network meta-analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Seven Chinese Patent Medicines in Combination with SSRIs for Treating Depressive Disorders

  • By

  • Hongye Geng

  • Lixuan Li

  • Chengyuan Lu

  • Shuling Wang

  • September 4, 2026

Share

  • 1

    An erratum was issued for a systematic review and network meta-analysis on Chinese patent medicines combined with SSRIs.

  • 2

    The correction addressed an error in Table 1 regarding the display of the comparator group 'SSRIs monotherapy'.

  • 3

    The corrected table enhances readability and supports accurate interpretation of the network meta-analysis.

  • 4

    Numerical values in the corrected table remain unchanged from the original analysis.

  • 5

    The correction does not alter the study's findings or conclusions.

Original Source(s)

Correction: Comparative efficacy and safety of seven Chinese patent medicines combined with SSRIs for depressive disorder: a systematic review and network meta-analysis

  • by Hongye Geng, Lixuan Li, Chengyuan Lu, Shuling Wang

  • September 4, 2026

Related Content

Neurogenic progression may falter in MDD

Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.

Nocturnal pain in elbow disorders may predict sleep quality

Prospective multicenter study found poorer sleep quality was associated with greater pain and functional disability across common elbow conditions.

Gender differences in the effects of economic inequality on mental conditions: a multivariate meta-analysis of Gini index and relative income position in high-income OECD countries